MCT INHIBITION SYNERGIZES WITH TYROSINE KINASE AND MTOR INHIBITOR TREATMENT IN RENAL CELL CARCINOMA

被引：0
|
作者：
Jambunathan, Bhaghyasree
Dergham, Abdo
Bhattacharjee, Sayani
Wynn, Rebecca
Sindhwani, Puneet
Petros, Firas
Nadiminty, Nagalakshmi
机构：
来源：
JOURNAL OF UROLOGY | 2022年 / 207卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD43-03
引用
收藏
页码：E702 / E702
页数：1
相关论文
共 50 条
  • [41] The role of tyrosine kinase inhibitors in the treatment of renal cell carcinoma with brain metastases
    Aytekin, Aydin
    Ciltas, Aydin
    Sahinli, Hayriye
    Benekli, Mustafa
    JOURNAL OF BUON, 2016, 21 (01): : 281 - 282
  • [42] Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
    Vasudev, Naveen S.
    Larkin, James M. G.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 333 - 342
  • [43] Focused Ultrasound-Triggered Release of Tyrosine Kinase Inhibitor From Thermosensitive Liposomes for Treatment of Renal Cell Carcinoma
    Abshire, Caleb
    Murad, Hakm Y.
    Arora, Jaspreet S.
    Liu, James
    Mandava, Sree Harsha
    John, Vijay T.
    Khismatullin, Damir B.
    Lee, Benjamin R.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (05) : 1355 - 1362
  • [44] Tyrosine-kinase inhibitor sorafenib (S) in treatment of metastatic renal cell carcinoma cancer (mRCC) with lung metastases
    Popova, Irina L.
    Vladimirova, Liubov Yu
    Abramova, Natalya A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Treatment of advanced renal cell carcinoma after tyrosine kinase inhibitor therapy: first experiences with Everolimus (Afinitor®) in practice
    Johannsen, M.
    Kempkensteffen, C.
    Miller, K.
    Weikert, S.
    ONKOLOGIE, 2010, 33 : 90 - 90
  • [46] Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma
    Oudard, Stephane
    Medioni, Jacques
    Aylllon, Jorge
    Barrascourt, Eduardo
    Elaidi, Reza-Thierry
    Balcaceres, Jose
    Scotte, Florian
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 705 - 717
  • [47] CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitors
    Emberley, E.
    Bennett, M.
    Chen, J.
    Gross, M.
    Huang, T.
    Li, W.
    Mackinnon, A.
    Pan, A.
    Rodriguez, M.
    Steggerda, S.
    Wang, T.
    Zhang, J.
    Zhang, W.
    Parlati, F.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S124 - S124
  • [48] Inhibition of hTERT expression by MAP kinase inhibitor induces cell death in renal cell carcinoma
    Pal, Deeksha
    Sharma, Ujjawal
    Singh, Shrawan Kumar
    Kakkar, Nandita
    Prasad, Rajendra
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (06) : 401 - 408
  • [49] Determinants of neoadjuvant immune checkpoint inhibitor plus tyrosine kinase inhibitor therapy response in renal cell carcinoma
    Gu, L.
    Liang, Q.
    Zhang, X.
    Wang, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1507 - S1507
  • [50] Novel tyrosine kinase inhibitors for renal cell carcinoma
    Dorff, Tanya B.
    Pal, Sumanta K.
    Quinn, David I.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (01) : 67 - 73
12345